Compare Stocks: FLNA, LENZ, VTVT, and AARD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AARD Aardvark Therapeutics	$5.02 -9.5%	$6.27	$3.35 ▼ $17.94	$121.46M	3.74	141,895 shs	64,152 shs
FLNA Cassava Sciences	$0.70 -3.1%	$0.94	$0.68 ▼ $4.98	$34.72M	-0.69	242,697 shs	445,973 shs
LENZ LENZ Therapeutics	$4.23 -5.4%	$5.16	$4.20 ▼ $50.40	$140.45M	0.66	607,169 shs	818,068 shs
VTVT vTv Therapeutics	$30.46 -3.1%	$32.55	$18.97 ▼ $44.00	$123.84M	0.29	44,741 shs	45,335 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AARD Aardvark Therapeutics	-9.55%	-5.82%	-23.24%	+31.41%	-49.55%
FLNA Cassava Sciences	-3.10%	-12.63%	-23.74%	-42.44%	-66.51%
LENZ LENZ Therapeutics	-5.37%	-20.64%	-10.57%	-33.28%	-89.43%
VTVT vTv Therapeutics	-3.12%	-7.11%	+1.13%	-10.20%	+49.24%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AARD Aardvark Therapeutics	$5.02 -9.5%	$6.27	$3.35 ▼ $17.94	$121.46M	3.74	141,895 shs	64,152 shs
FLNA Cassava Sciences	$0.70 -3.1%	$0.94	$0.68 ▼ $4.98	$34.72M	-0.69	242,697 shs	445,973 shs
LENZ LENZ Therapeutics	$4.23 -5.4%	$5.16	$4.20 ▼ $50.40	$140.45M	0.66	607,169 shs	818,068 shs
VTVT vTv Therapeutics	$30.46 -3.1%	$32.55	$18.97 ▼ $44.00	$123.84M	0.29	44,741 shs	45,335 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AARD Aardvark Therapeutics	-9.55%	-5.82%	-23.24%	+31.41%	-49.55%
FLNA Cassava Sciences	-3.10%	-12.63%	-23.74%	-42.44%	-66.51%
LENZ LENZ Therapeutics	-5.37%	-20.64%	-10.57%	-33.28%	-89.43%
VTVT vTv Therapeutics	-3.12%	-7.11%	+1.13%	-10.20%	+49.24%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AARD Aardvark Therapeutics	2.42	Hold	$15.33	205.44% Upside
FLNA Cassava Sciences	2.00	Hold	$5.00	617.88% Upside
LENZ LENZ Therapeutics	2.50	Moderate Buy	$28.80	580.85% Upside
VTVT vTv Therapeutics	2.78	Moderate Buy	$55.83	83.30% Upside

Current Analyst Ratings Breakdown

Latest FLNA, LENZ, VTVT, and AARD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/9/2026	LENZ LENZ Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/7/2026	VTVT vTv Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
9/2/2026	VTVT vTv Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/25/2026	LENZ LENZ Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/13/2026	LENZ LENZ Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/12/2026	LENZ LENZ Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$12.00 ➝ $7.00
8/12/2026	LENZ LENZ Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/11/2026	LENZ LENZ Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/11/2026	VTVT vTv Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D-)
8/7/2026	VTVT vTv Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/6/2026	VTVT vTv Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$45.00 ➝ $42.00

(Data available from 9/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	$4.90 per share	N/A
FLNA Cassava Sciences	N/A	N/A	N/A	N/A	$1.54 per share	N/A
LENZ LENZ Therapeutics	$19.09M	6.96	N/A	N/A	$9.09 per share	0.47
VTVT vTv Therapeutics	$1.02M	117.66	N/A	N/A	$16.36 per share	1.86

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AARD Aardvark Therapeutics	-$57.59M	-$3.21	N/A	N/A	N/A	N/A	-71.54%	-64.94%	N/A
FLNA Cassava Sciences	-$90.97M	-$0.87	N/A	N/A	N/A	N/A	-58.78%	-36.74%	N/A
LENZ LENZ Therapeutics	-$82.13M	-$4.09	N/A	N/A	N/A	-586.74%	-53.39%	-49.14%	11/4/2026 (Estimated)
VTVT vTv Therapeutics	-$26.97M	-$1.06	N/A	N/A	N/A	N/A	-6.27%	-5.06%	11/5/2026 (Estimated)

Latest FLNA, LENZ, VTVT, and AARD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	AARD Aardvark Therapeutics	-$0.87	-$0.66	+$0.21	-$0.66	N/A	N/A
8/11/2026	Q2 2026	LENZ LENZ Therapeutics	-$1.05	-$1.02	+$0.03	-$1.02	$2.38 million	$5.49 million
8/6/2026	Q2 2026	VTVT vTv Therapeutics	-$0.97	-$1.05	-$0.08	-$1.05	$0.33 million	N/A
7/29/2026	Q2 2026	FLNA Cassava Sciences	N/A	-$0.18	N/A	-$0.18	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A
FLNA Cassava Sciences	N/A	N/A	N/A	N/A	N/A
LENZ LENZ Therapeutics	N/A	N/A	N/A	N/A	N/A
VTVT vTv Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AARD Aardvark Therapeutics	N/A	12.63	12.63
FLNA Cassava Sciences	N/A	2.08	2.08
LENZ LENZ Therapeutics	N/A	13.55	13.31
VTVT vTv Therapeutics	N/A	12.48	12.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AARD Aardvark Therapeutics	N/A
FLNA Cassava Sciences	38.05%
LENZ LENZ Therapeutics	54.32%
VTVT vTv Therapeutics	17.51%

Insider Ownership

Company	Insider Ownership
AARD Aardvark Therapeutics	17.80%
FLNA Cassava Sciences	4.60%
LENZ LENZ Therapeutics	8.30%
VTVT vTv Therapeutics	5.99%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AARD Aardvark Therapeutics	28	21.88 million	17.99 million	N/A
FLNA Cassava Sciences	20	48.31 million	46.09 million	Optionable
LENZ LENZ Therapeutics	152	31.42 million	28.81 million	N/A
VTVT vTv Therapeutics	26	3.94 million	3.70 million	Not Optionable

FLNA, LENZ, VTVT, and AARD Headlines

Recent News About These Companies

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - September 15, 2026

September 15 at 11:17 PM | biospace.comB

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

September 15 at 4:05 PM | globenewswire.com

vTv Therapeutics Inc. (NASDAQ:VTVT) Receives Consensus Recommendation of "Moderate Buy" from Analysts

September 12, 2026 | marketbeat.com

vTv Therapeutics (NASDAQ:VTVT) Raised to Hold at Zacks Research

September 9, 2026 | marketbeat.com

Lifesci Capital Upgrades vTv Therapeutics (NASDAQ:VTVT) to Strong-Buy

September 4, 2026 | marketbeat.com

Analysts Conflicted on These Healthcare Names: Kymera Therapeutics (KYMR) and vTv Therapeutics (VTVT)

September 3, 2026 | theglobeandmail.com

vTv Therapeutics to Participate in September Investor Conferences

September 2, 2026 | globenewswire.com

vTv Therapeutics (NASDAQ:VTVT) Stock Price Passes Below 50-Day Moving Average - Should You Sell?

September 2, 2026 | marketbeat.com

vTv Therapeutics Inc. Cl A

August 30, 2026 | barrons.com

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

August 19, 2026 | globenewswire.com

vTv Therapeutics Inc. (NASDAQ:VTVT) Given Average Rating of "Moderate Buy" by Analysts

August 18, 2026 | marketbeat.com

vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 7, 2026 | markets.businessinsider.com

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

July 28, 2026 | globenewswire.com

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

July 2, 2026 | globenewswire.com

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

June 2, 2026 | globenewswire.com

vTv Therapeutics Inc. (NASDAQ:VTVT) Just Beat Earnings: Here's What Analysts Think Will Happen Next

May 17, 2026 | finance.yahoo.com

Why vTv Therapeutics Inc.’s (VTVT) Stock Is Down 8.13%

May 16, 2026 | aaii.comA

vTv Therapeutics (VTVT) is on the Move, Here's Why the Trend Could be Sustainable

May 15, 2026 | zacks.com

vTv Therapeutics Expands At-The-Market Share Program Capacity

May 13, 2026 | tipranks.com

vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 13, 2026 | globenewswire.com

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 8, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLNA, LENZ, VTVT, and AARD Company Descriptions

Aardvark Therapeutics NASDAQ:AARD

$5.02 -0.53 (-9.55%)

Closing price 09/15/2026 04:00 PM Eastern

Extended Trading

$5.02 +0.00 (+0.02%)

As of 07:45 AM Eastern

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Cassava Sciences NASDAQ:FLNA

$0.70 -0.02 (-3.10%)

As of 09/15/2026 04:00 PM Eastern

Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.

LENZ Therapeutics NASDAQ:LENZ

$4.23 -0.24 (-5.37%)

Closing price 09/15/2026 04:00 PM Eastern

Extended Trading

$4.28 +0.05 (+1.09%)

As of 07:01 AM Eastern

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

vTv Therapeutics NASDAQ:VTVT

$30.46 -0.98 (-3.12%)

Closing price 09/15/2026 04:00 PM Eastern

Extended Trading

$30.44 -0.03 (-0.08%)

As of 07:34 AM Eastern

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FLNA, LENZ, VTVT, and AARD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FLNA, LENZ, VTVT, and AARD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FLNA, LENZ, VTVT, and AARD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLNA, LENZ, VTVT, and AARD Company Descriptions

Aardvark Therapeutics NASDAQ:AARD

Cassava Sciences NASDAQ:FLNA

LENZ Therapeutics NASDAQ:LENZ

vTv Therapeutics NASDAQ:VTVT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FLNA, LENZ, VTVT, and AARD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FLNA, LENZ, VTVT, and AARD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FLNA, LENZ, VTVT, and AARD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLNA, LENZ, VTVT, and AARD Company Descriptions

Aardvark Therapeutics NASDAQ:AARD

Cassava Sciences NASDAQ:FLNA

LENZ Therapeutics NASDAQ:LENZ

vTv Therapeutics NASDAQ:VTVT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools